मैगज़्टर गोल्ड के साथ असीमित हो जाओ
10,000 से अधिक पत्रिकाओं, समाचार पत्रों और प्रीमियम कहानियों तक असीमित पहुंच प्राप्त करें सिर्फ
BioNTech Acquires CureVac for $1.2 Billion to Boost Cancer Biz
Mint Bangalore
|June 13, 2025
BioNTech SE has agreed to buy former COVID vaccine rival CureVac NV for about $1.25 billion in an all-stock transaction to boost its growing oncology business.
CureVac investors will get around $5.46 in BioNTech shares for each CureVac one, the companies said Thursday. The price represents a 34% premium to CureVac's closing share price on Wednesday.
CureVac shareholders will own 4% to 6% of BioNTech once the transaction closes. The deal caps decades of rivalry, which came to a head during the race to develop a COVID vaccine. BioNTech had won the race with its partner Pfizer Inc., to transform into one of Europe's leading biotechs. CureVac's shot never made it to the market after proving less effective in clinical trials.
यह कहानी Mint Bangalore के June 13, 2025 संस्करण से ली गई है।
हजारों चुनिंदा प्रीमियम कहानियों और 10,000 से अधिक पत्रिकाओं और समाचार पत्रों तक पहुंचने के लिए मैगज़्टर गोल्ड की सदस्यता लें।
क्या आप पहले से ही ग्राहक हैं? साइन इन करें
Mint Bangalore से और कहानियाँ
Mint Bangalore
China's export boom hurts the job prospects of Asia’s Gen-Z
Manufacturing jobs are vanishing as cheap Chinese goods flood in
3 mins
December 19, 2025
Mint Bangalore
RBI clean-up forces rethink on NBFC-fintech co-lending
Co-lending relationships between regulated lenders such as banks and non-banking finance companies (NBFCs) on one side and fintech firms on the other are seen changing significantly in the next three to five years, experts said at a Mint BFSI Summit panel discussion.
2 mins
December 19, 2025
Mint Bangalore
Why IndiGo is Sensex’s worst newcomer
IndiGo's parent, InterGlobe Aviation Ltd, has suffered a sharp selloff due to its operational meltdown days before inclusion in the BSE Sensex.
2 mins
December 19, 2025
Mint Bangalore
All that cheap Chinese stuff is now Europe's problem
Trump's tariffs have redirected the flow of low-valued packages away from the U.S. into backyard warehouses on the Continent; the 'new Silk Road'
8 mins
December 19, 2025
Mint Bangalore
L Catterton bets on Haldiram Snacks
Consumer-focused global investment firm L Catterton has invested an undisclosed amount in Temasek-backed Haldiram Snacks Food Pvt. Ltd and entered into a strategic partnership, as private equity interest in India’s snacks and packaged foods sector continues to rise.
1 min
December 19, 2025
Mint Bangalore
SHANTI bill to open up nuclear sector gets RS nod amid concerns
The Rajya Sabha on Thursday passed the bill to open up nuclear power generation to the private sector and ease liabilities on suppliers amid the Opposition's concerns over allowing private players in the sector and the lack of liabilities for suppliers of components.
1 mins
December 19, 2025
Mint Bangalore
How child-free couples are rethinking retirement math
Focus is on flexibility, experiences and early retirement over traditional child-centric targets
3 mins
December 19, 2025
Mint Bangalore
Nuclear recharge: Let's hedge our import bets
India's new nuclear law aligns our framework with global norms and looks set to revive a languishing source of clean energy. But don't give up on efforts to minimize import reliance
2 mins
December 19, 2025
Mint Bangalore
India's RDI Fund: We just cannot afford to miss our R&D moment
The Centre's big push is in the right direction but outcomes will depend on how well we redesign the broader R&D ecosystem
2 mins
December 19, 2025
Mint Bangalore
Sumitomo Realty bets on Mumbai
Japan’s Sumitomo Realty and Development, the country’s third-largest developer, plans to expand in India with an unusual strategy: focusing on Mumbai and managing apartments rather than selling them, executives told Reuters.
1 min
December 19, 2025
Listen
Translate
Change font size